HC gp39 and CRP serum levels in: IBD-A, IBD-nonA, aIBD, and naIBD subgroups with and without arthritis
| Subgroups | Patients (n) | HC gp39 (ng/ml) | CRP (mg/l) |
|---|---|---|---|
| Serum levels of HC gp39 and CRP in aIBD-A, naIBD-A, aIBD-nonA, naIBD-nonA, and controls. The Kruskal-Wallis analysis: v naIBD-nonA *p<0.05, †p<0.01, ‡p<0.001; v controls §p<0.05, ¶p<0.001. | |||
| aIBD-A | 20 | 122.6 (78.6)‡§ | 24.5 (35)¶ |
| naIBD-A | 43 | 105.8 (97.6)† | 10.4 (14)¶ |
| aIBD-nonA | 16 | 72.6 (49) | 22.4 (18.5)*¶ |
| naIBD-nonA | 42 | 58.4 (49.4) | 5.1 (6.1)§ |
| Controls | 20 | 51.9 (14.1) | 1.3 (1.5) |